Maribavir for treating refractory cytomegalovirus infection after transplant
Evidence-based recommendations on maribavir (Livtencity) for cytomegalovirus infection in adults after transplant.
Commercial arrangement
There is a simple discount patient access scheme for maribavir. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisat...